OncoSec Medical (OTCBB:ONCS.OB) said Thursday that its executive management team will be attending the JP Morgan Healthcare Conference in San Francisco on January 9-11.
The company said its president and CEO Punit Dhillon will be presenting a company update at two investor conferences held concurrently with the JP Morgan Conference.
OncoSec develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics.
Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes.
OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment